Direkt zum Inhalt
Merck

Fortfahren mit

A1908

Asialofetuin aus Kälberserum fötal

Type II (Sigma designation)

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
Ihnen/SKUVerfügbarkeitPreis
50 mg
Warenkorb auf Verfügbarkeit prüfen
€ 607,00

Über diesen Artikel

UNSPSC Code:
12352202
NACRES:
NA.61
MDL number:
Form:
powder
Biological source:
bovine

€ 607,00


Warenkorb auf Verfügbarkeit prüfen

Sonderanfertigung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

bovine

Quality Segment

type

Type II (Sigma designation)

form

powder

technique(s)

activity assay: suitable, inhibition assay: suitable

impurities

salt, essentially free, ≤1.0% N-acetylneuraminic acid

solubility

H2O: soluble 1.0 mg/mL, clear to hazy, colorless to very faintly yellow

storage temp.

2-8°C

Application

Das Einbringen von Asialofetuin (AF) in Liposome verstärkt die Abgabe an und die Endozytose von Zellen, die den AF-Rezeptor aufweisen, insbesondere Hepatozyten, signifikant. Dieses bietet einen sehr effizienten Weg für die Gentherapie.
Asialofetuin from fetal calf serum is suitable for use:
  • in the assay of the lactose binding activity of the galectin-7 by immunodetection of in situ binding activity to asialofetuin immobilized on nitrocellulose[1]
  • in the inhibition of zona pellucida hardening of mouse oocytes[2]
  • as an acceptor in sialyltransferase enzyme activity assay[3]

Biochem/physiol Actions

Feutins are glycoproteins that belong to the cystatin superfamily. They are characterized by the presence of two tandemly arranged cystatin-like domains and an unrelated domain.[4] It binds to transforming growth factor (TGF)-β/BMP (bone morphogenic protein) cytokines.[5]
Asialofetuin (AF) binds to asialoglycoprotein receptor (ASGP-R) and is employed as a ligand for drug delivery to the hepatocytes. It aids serum-resistant lipoplexes for efficient gene deliver into the HepG2 (human hepatoblastoma) cells.

Preparation Note

Enzymatic cleavage using neuraminidase

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
A4781F2379H5505
biological source

bovine

biological source

bovine (calf) serum

biological source

bovine serum (fetal)

biological source

bovine (calf) thymus

technique(s)

activity assay: suitable, inhibition assay: suitable

technique(s)

-

technique(s)

cell culture | mammalian: suitable

technique(s)

activity assay: suitable

form

powder

form

powder

form

lyophilized powder

form

powder

impurities

salt, essentially free, ≤1.0% N-acetylneuraminic acid

impurities

salt, essentially free, ≤0.5% N-acetylneuraminic acid

impurities

≤0.3% free N-acetylneuraminic acid

impurities

-

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

Quality Level

200

Quality Level

300

Quality Level

200

Quality Level

200


Still not finding the right product?


Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Questions

  1. What is the difference in Type 1 versus Type II asialofetuin?

    1 answer
    1. The difference between the Type I and Type II Asialofetuin products does not represent any kind of biochemical or functional difference. These indicate different methods of production and purification. The Type II option, product A1908, utilizes neuraminadase in an enzymatic cleavage step. The Type I, product A4781, utilizes a proprietary modification of that described in Spiro, R.G., J. Biol. Chem., 235, 2860 (1960).

      Helpful?

Reviews

No rating value

Active Filters